Patents by Inventor Erhad Ascic

Erhad Ascic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of the NMDA receptor
    Patent number: 11466027
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220220077
    Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 14, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Morten Jørgensen, Erhad Ascic, Martin Juhl, Klaus Gjervig Jensen, Ask Püschl, Benny Bang-Andersen
  • PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20220213117
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: January 25, 2022
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • CATECHOLAMINE CARBAMATE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220213040
    Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: July 7, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Morten Jørgensen, Erhad Ascic, Karin Sjödin, Klaus Gjervig Jensen, Jarkko Tapani Rautio
  • Prodrugs of modulators of the NMDA receptor
    Patent number: 11358971
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: June 14, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20210047342
    Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: June 30, 2020
    Publication date: February 18, 2021
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • MODULATORS OF THE NMDA RECEPTOR
    Publication number: 20210002292
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Application
    Filed: June 30, 2020
    Publication date: January 7, 2021
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David